Transcode Therapeutics Total Operating Expenses Over Time
| RNAZ Stock | USD 0.38 0.04 11.76% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Transcode Therapeutics Performance and Transcode Therapeutics Correlation. Transcode |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Transcode Therapeutics. If investors know Transcode will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Transcode Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 168.84 | Return On Assets (2.08) | Return On Equity (10.49) |
The market value of Transcode Therapeutics is measured differently than its book value, which is the value of Transcode that is recorded on the company's balance sheet. Investors also form their own opinion of Transcode Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Transcode Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Transcode Therapeutics' market value can be influenced by many factors that don't directly affect Transcode Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Transcode Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Transcode Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Transcode Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Operating Expenses Analysis
Compare Transcode Therapeutics and related stocks such as Landos Biopharma, Neximmune, and Oncorus Total Operating Expenses Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XBIO | 5.5 M | 5.5 M | 5.5 M | 9.6 M | 12.9 M | 9.8 M | 50.4 M | 11 M | 7.3 M | 9.6 M | 5.1 M | 6.9 M | 8.4 M | 7.1 M | 9.6 M |
| RVPHW | 376.9 K | 376.9 K | 376.9 K | 376.9 K | 376.9 K | 376.9 K | 376.9 K | 376.9 K | 376.9 K | 376.9 K | 2.4 M | 10.1 M | 24.3 M | 39.5 M | 41.5 M |
| EYEN | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 3.5 M | 5.1 M | 17.3 M | 21.3 M | 21 M | 25.3 M | 26.9 M | 25.4 M | 18.3 M |
| CGTX | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 6.6 M | 11.2 M | 21.3 M | 50.7 M | 53.3 M |
| KOD | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 25.5 M | 26.4 M | 49.2 M | 136 M | 267.1 M | 341.4 M | 277.3 M | 156.7 M |
| IMMX | 842.5 K | 842.5 K | 842.5 K | 842.5 K | 842.5 K | 842.5 K | 842.5 K | 842.5 K | 842.5 K | 842.5 K | 453.9 K | 1.4 M | 8.2 M | 16.1 M | 16.9 M |
| CNSP | 516.3 K | 516.3 K | 516.3 K | 516.3 K | 516.3 K | 516.3 K | 516.3 K | 516.3 K | 881.8 K | 3.8 M | 9.5 M | 14 M | 15.3 M | 18.9 M | 9.9 M |
| SONN | 935.1 K | 935.1 K | (23.3 M) | 23.3 M | 23.3 M | 10.8 M | 4.5 M | 3.9 M | 3.9 M | 4.7 M | 25.6 M | 30 M | 7.1 M | 4.7 M | 4.5 M |
| REVB | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 17.4 M | 26.5 M | 38.1 M | 42.1 M | 3.6 K | 145.5 K | 12 M | 10.9 M | 8.7 M | 13.5 M |
| ZURA | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 2.7 M | 62.6 M | 65.8 M |
| PHIO | 12.8 M | 12.8 M | 13.1 M | 21.3 M | 8.9 M | 10.3 M | 9 M | 9.4 M | 7.5 M | 9 M | 8.8 M | 13.5 M | 11.5 M | 4.5 M | 8.6 M |
| ZVSA | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 7.7 M | 13 M | 14.4 M | 12.9 M |
Transcode Therapeutics and related stocks such as Landos Biopharma, Neximmune, and Oncorus Total Operating Expenses description
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.My Equities
My Current Equities and Potential Positions
| Transcode Therapeutics | RNAZ |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.38
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.